LFWD vs IRBT vs NVCR vs ISRG

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -23. 4% for iRobot Corporation (IRBT). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 2x trailing P/E (43. 3x forward), making it the more compelling value choice. Analysts rate Lifeward Ltd. (LFWD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +61. 7%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus LFWD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.

(ISRG) is the lower-risk stock at 1. 00β versus iRobot Corporation's 5. 31β — meaning IRBT is approximately 432% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -23. 4% for iRobot Corporation (IRBT). On earnings-per-share growth, the picture is similar: Lifeward Ltd. grew EPS 57. 1% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, LFWD leads at 58. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -90. 4% for Lifeward Ltd. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -76. 7% for LFWD. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 87.

3% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Intuitive Surgical, Inc.

(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +549. 2% 10Y return). iRobot Corporation (IRBT) carries a higher beta of 5. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +549. 2%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LFWD (Healthcare) and IRBT (Consumer Cyclical) and NVCR (Healthcare) and ISRG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LFWD is a small-cap quality compounder stock; IRBT is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.